Combination treatment with ruxolitinib and pegylated interferon-alpha may be an effective treatment in myeloproliferative neoplasms (MPNs) , experimental work at the QIMR Berghofer Medical Research Institute research has suggested. Published in Leukemia, the results from a murine model confirmed the drugs target two different pathways in MPN. Senior co-author and haematologist Associate Professor Steven Lane ...
Closing in on better interferon-based treatments for MPN
By Mardi Chapman
21 Nov 2019